Skip to main content
Signal8
Launch Terminal

Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Rein Therapeutics Inc. logo

Rein Therapeutics Inc.

NASDAQ:RNTXHealthcare
-7.79%$0.6700
AH$0.6700+0.00%vs close
Mkt Cap$57.8M
Float86.18M
O/S86.27M
Vol
$ Vol
RVOL
Inst Own47.2%
SI0.7%
Earnings
Dilution
Rein Therapeutics Inc. logoNASDAQ:RNTX$0.6700-7.79%
Phase Distribution
9 lead-sponsored trials·1 active·6 completed
Phase 16
Phase 1/21
Phase 22
(1 more as collaborator)
Status Overview
Recruiting1
Completed6
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

    LTI-01, Placebo

    Pleural Effusion

    Enrollment
    44
    Start
    Sep 2020
    Primary Completion
    Mar 2022
    Completion
    Jul 2022
    NCT04159831
  • Phase 2
    Recruiting

    A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    LTI-03, Placebo

    Idiopathic Pulmonary Fibrosis (IPF)

    Enrollment
    120
    Start
    Feb 2026
    Primary Completion
    Sep 2027est.
    Completion
    Dec 2027est.
    NCT06968845
  • Phase 1/2
    Completed

    ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

    ALRN-6924

    Solid Tumor, Lymphoma +1

    Enrollment
    142
    Start
    Oct 2014
    Primary Completion
    Mar 2020
    Completion
    Apr 2020
    NCT02264613
  • Phase 1
    Completed

    Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

    ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg

    Growth Hormone Deficiency

    Enrollment
    33
    Start
    Jan 2013
    Primary Completion
    May 2013
    Completion
    May 2013
    NCT01775358
  • Phase 1
    Completed

    Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

    ALRN-6924, ALRN-6924 in combination with cytarabine

    Acute Myeloid Leukemia, Myelodysplastic Syndromes

    Enrollment
    55
    Start
    Sep 2016
    Primary Completion
    Apr 2019
    Completion
    Aug 2019
    NCT02909972
  • Phase 1
    Terminated

    A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

    ALRN-6924, Carboplatin

    Non Small Cell Lung Cancer, Small-cell Lung Cancer

    Enrollment
    35
    Start
    Sep 2019
    Primary Completion
    Jul 2022
    Completion
    Aug 2022
    NCT04022876
  • Phase 1
    Completed

    Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

    Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03), Placebo

    Idiopathic Pulmonary Fibrosis

    Enrollment
    71
    Start
    Jan 2020
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT04233814
  • Phase 1
    Terminated

    A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

    ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)

    Prevention of Chemotherapy-induced Myelosuppression

    Enrollment
    6
    Start
    Jan 2023
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT05622058
  • Phase 1
    Completed

    A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

    LTI-03, Placebo

    Idiopathic Pulmonary Fibrosis

    Enrollment
    24
    Start
    Jul 2023
    Primary Completion
    Sep 2024
    Completion
    Sep 2024
    NCT05954988
Search ClinicalTrials.gov for “Rein Therapeutics”